2,627 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Quantbot Technologies LP

Quantbot Technologies LP bought a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,627 shares of the company’s stock, valued at approximately $83,000.

Several other large investors also recently added to or reduced their stakes in IDYA. California State Teachers Retirement System lifted its stake in shares of IDEAYA Biosciences by 19.0% in the 1st quarter. California State Teachers Retirement System now owns 57,535 shares of the company’s stock valued at $2,525,000 after purchasing an additional 9,176 shares during the last quarter. Comerica Bank boosted its stake in shares of IDEAYA Biosciences by 723.5% during the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock worth $66,000 after acquiring an additional 1,324 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of IDEAYA Biosciences by 411.3% during the 2nd quarter. SG Americas Securities LLC now owns 11,775 shares of the company’s stock valued at $413,000 after acquiring an additional 9,472 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of IDEAYA Biosciences by 38.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock valued at $117,000 after acquiring an additional 927 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in IDEAYA Biosciences by 43.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 316,492 shares of the company’s stock worth $11,112,000 after purchasing an additional 95,129 shares during the last quarter. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Price Performance

IDYA opened at $27.79 on Friday. The company has a market capitalization of $2.40 billion, a P/E ratio of -11.93 and a beta of 0.79. The firm’s fifty day moving average price is $29.18 and its two-hundred day moving average price is $34.92. IDEAYA Biosciences, Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same quarter last year, the business earned ($0.46) EPS. On average, equities research analysts expect that IDEAYA Biosciences, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on IDYA. Oppenheimer reiterated an “outperform” rating and set a $53.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Stephens initiated coverage on shares of IDEAYA Biosciences in a research note on Monday, November 18th. They issued an “overweight” rating and a $51.00 target price on the stock. Stifel Nicolaus boosted their target price on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Wedbush reaffirmed an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a research report on Monday, November 4th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $53.67.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.